These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23700464)

  • 1. In vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pH.
    Argemi X; Hansmann Y; Christmann D; Lefebvre S; Jaulhac B; Jehl F
    PLoS One; 2013; 8(5):e64218. PubMed ID: 23700464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
    Luther MK; Arvanitis M; Mylonakis E; LaPlante KL
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4612-20. PubMed ID: 24867993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM;
    J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.
    Furustrand Tafin U; Majic I; Zalila Belkhodja C; Betrisey B; Corvec S; Zimmerli W; Trampuz A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4821-7. PubMed ID: 21807979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.
    Rice LB; Eliopoulos GM; Moellering RC
    Antimicrob Agents Chemother; 1989 Apr; 33(4):470-3. PubMed ID: 2543282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.
    Louie A; Baltch AL; Ritz WJ; Smith RP; Asperilla M
    Chemotherapy; 1993; 39(5):302-9. PubMed ID: 8396526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.
    Markowitz SM; Wells VD; Williams DS; Stuart CG; Coudron PE; Wong ES
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1075-80. PubMed ID: 1929246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis.
    Zheng JX; Sun X; Lin ZW; Qi GB; Tu HP; Wu Y; Jiang SB; Chen Z; Deng QW; Qu D; Yu ZJ
    J Med Microbiol; 2019 Mar; 68(3):493-502. PubMed ID: 30882300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis.
    Kussmann M; Schuster L; Zeitlinger M; Pichler P; Reznicek G; Wiesholzer M; Burgmann H; Poeppl W
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2257-63. PubMed ID: 26337433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
    Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
    Vouillamoz J; Moreillon P; Giddey M; Entenza JM
    J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.